Introduction {#S1}
============

Rates of enterococcal infections among patients in intensive care increased dramatically in the last two decades worldwide.^[@R1]^ Enterococcal isolates (*Enterococcus faecalis* and *E. faecium*) are ranked as the second most important nosocomial pathogen in intensive crare unit (ICU) acquired bloodstream infections in Europe.^[@R2]^ Infections occur in severely ill and immuno-compromised patients revealing also premature babies and newborns at risk for acquiring enterococcal infections.^[@R3],[@R4]^ Transmission rates of enterococcal isolates are high among nosocomial patients, even higher than for *S. aureus* and *E. coli*.^[@R5]^ Increased importance of enterococci especially *E. faecium* as a nosocomial pathogen is linked to a preferred prevalence of hospital-associated strain types that possess acquired antibiotic resistance properties, specific molecular markers and clonal types identifiable by molecular typing techniques such as Multi-locus sequence typing (MLST).^[@R6]^ On the other hand, commensal clonal types of *E. faecalis* and *E. faecium* exhibit important constituents of the healthy human intestinal flora and are among the first and early colonizers of the infants\' intestines.^[@R7]^ In the present study we investigated rectal (and skin) colonization, cross-transmission rates and clonal types of enterococci among newborns of a neonatal ICU of a German hospital over a period of two months.

Brief Report {#S2}
============

From April to May 2006, 20 patients attending a German neonatal ICU were screened for bacterial rectal and skin colonizations. All newborns were admitted to a separate ward and were kept aside from other pediatric patients. Samples were taken in relation to clinical signs of infection of the babies (fever, etc.) or when mothers had risk factors or infections (amnion infection, vaginal group B streptococcus colonization, etc). Potentially pathogenic bacteria such as *Staphylococcus aureus*, coagulase-negative staphylococci, *Enterobacteriaceae* and *Enterococcus* spp. were assessed. Five patients were rectally screened consecutively, two and three times, respectively ([Table 1](#T1){ref-type="table"}). Rectal and skin samples were primarily screened on two non-selective media; Brilliance UTI Clarity agar (Oxoid/Thermo Fischer Scientific, Wesel, Germany) and Trypticase Soy-Agar + 5% Sheep Blood (bioMerieux, Nuertingen, Germany). Morphologically different isolates per sample were further identified by Vitek® 2 (bioMerieux, Nürtingen, D). All but three enterococcal isolates were available for a subsequent analysis. Antibiotic susceptibilities for enterococci were initially determined by VITEK® 2 (bioMérieux, according to CLSI criteria and later confirmed by an in house microbroth dilution method.^[@R8]^ Epidemiological markers to differentiate hospital-associated strains of *E. faecium* from colonizing variants were determined by PCR as described recently (*esp, hyl~Efm~, IS*16)..^[@R9],[@R10]^ To investigate clonal relatedness of strains macrorestriction analysis in Pulsed-Field Gel Electrophoresis was performed as described^[@R9]^ and subsequent analysis was done using a Dice coefficient and UPGMA clustering (BioNumercis v. 5.1; Applied Maths, Belgium). Multi-locus sequence typing (MLST) was performed to differentiate between commensal and hospital-associated strain types as given elsewhere ([http://efaeci-um.mlst.net/](http://efaecium.mlst.net/) and <http://efaecalis.mlst.net/>).

Table 1Microbiological results of the rectal screenings of all neonatal intensive care unit patients during a two-months\' period. Only potentially pathogenic bacteria of the genera *Staphylococcus*, *Enterococcus, Acinetobacter* and the family Enterobacteriaceae were assessed.Date (DD/MM)Patient No.Age at admission (days)EnterococcusOther bacteriaInfection / SepsisGestational age in weeks (+days)Birth weight (g)Clinical situation (child)Antibiotic treatmentRemarks04/0410NoNoNo382.920Only monitoring04/0420Yes*Escherichia coli*No31 (+2)1.175Apnea, bronchopulmonaryPremature infant dysplasia11/04Yes*E. coli, Streptococcus agalactiae*No18/04Yes*E. coli*No04/0437Yes*Klebsiella oxytocha; Staphylococcus epidermidis*No393.110Galactosaemia04/0440No*S. epidermidis*No403.960AsphyxiaMother: spontaneous cardiac arrest during birth11/04Yes*E. coli,* MRSENo04/0450Yes*E. coli,* MRSEYes28 (+0)740Sepsis, anaemia, hyperbilirubinaemia, respiratory distress syndrome, bronchopulmonary dysplasiaAMP/GEN VAN/CTXPremature infant11/04Yes[\*](#TF1-1){ref-type="table-fn"}*E. coli,* MRSE04/0460Yes*E. coli, S. epidermidis*No414.360Hypertrophia, hyperglobulia11/0470No*E. coli*Yes404.330Hypertrophia, perinatal infectionAMP/GEN11/0480Yes*E. coli*Yes403.320Perinatal infectionAMP/GEN PIP/GEN11/0490NoNoNo35 (+2)2.245Respiratory distress syndromePremature infant18/04Yes[\*](#TF1-1){ref-type="table-fn"}NoNo11/04100Yes*E. coli,* MRSENo383.820Unknown syndrome with micrognathia and apnea18/04113Yes*E. coli, S. epidermidis, Proteus mirabilis*Yes413.670Perinatal infectionAMP/GEN*P. mirabilis* from stomach aspirate25/04124Yes*E. coli*Yes383.610Omphalitis, conjunctivitisAMP/GEN ECO25/04133Yes[\*](#TF1-1){ref-type="table-fn"}*Acinetobacter spp.*No402.410Ventriculum septum defectBacterial growth from nasal swab03/05140YesYes32 (+0)1.970Hypoglycaemia, respiratory distress syndrome, perinatal infectionMother: MTR, AMP, CXM Baby: AMP/GEN; CTXPremature infant09/05Yes*E. coli*09/05150YesMRSA, MRSE(Yes)32 (+2)1.640Respiratory distress syndrome, Ductus omphalomesentericusAMP/GENPremature infant; initial antibiotic therapy terminated after 3 days09/05160Yes*S. epidermidis, Enterobacter cloacae*Yes413.560Perinatal infection, conjunctivitisAMP/CTX ECOBacterial growth from ear swab09/05170Yes*E. coli*Yes383.545Perinatal infection, respiratory distress syndromeAMP/CTX09/05182Yes*S. epidermidis, E. cloacae*Yes404.150Omphalitis, perinatal infectionAMP/GEN CTX25/05190Yes*S. epidermidis*No353.100PneumoniaBacterial growth from skin swab; viral pneumonia[^3][^4]

Results {#S3}
=======

Of the 20 screened neonatal patients only two samples did not grow bacteria at all (of the genera and species described above; [Table 1](#T1){ref-type="table"}). Ten neonatal patients showed signs of an infection and received immediate antibiotic treatment ([Table 1](#T1){ref-type="table"}). Screening samples of 18 patients grew enterococci and from 14 children isolates were accessible. From two patients consecutive isolates were analyzed ([Figure 1](#F1){ref-type="fig"}). Altogether eight *E. faecalis* and eight *E. faecium* isolates were available for a molecular analysis. Antibiotic susceptibility testing revealed a very small spectrum of acquired resistances; mainly erythromycin (*E. faecium*) and tetracycline (*E. faecalis*; [Figure 1](#F1){ref-type="fig"}) representing widespread acquired resistance characteristics also prevalent among animal, environmental and human colonizing, commensal enterococcal strains. Molecular markers of hospital-associated *E. faecium* strains (*esp, hyl~Efm~*, IS16) were absent in the eight *E. faecium* isolates. MLST results confirmed prevalence of commensal *E. faecium* strain types among the investigated patients ([Figure 1](#F1){ref-type="fig"}). Four isolates of *E. faecalis* revealed MLST strain type ST40 known to be highly prevalent among various ecological sources and which is also isolated from severe invasive infections like endocarditis and sepsis^[@R11]^ and from cases of bovine mastitis (Zischka and Werner, unpublished data). However, hospital-associated strain types belonging to clonal complexes CC2 and CC9 were not identified among the *E. faecalis* isolates. Cross transmission between the newborn babies attending the neonatal ICU at the same time period was demonstrated for *E. faecium* and *E. faecalis* isolates as well as ongoing colonization with identical strain types in single neonates ([Figure 1](#F1){ref-type="fig"}).

Figure 1*Sma*I macrorestriction patterns in Pulsed-Field Gel Electrophoresis (PFGE) of all enterococcal isolates colonizing neonatal patients. Clusters of related isolates from samples of different neonates suggest horizontal transmission between patients (clonal spread), for instance, isolates *E. faecalis* UW6724 \[Patient no. 3\], UW6731 \[Patient no. 4\], and UW6726 \[Patient no. 6\]. MLST types in parentheses are predicted according to an identical PFGE profile. Profiles ST-NEW1 and ST-NEW2 are new MLST types due to new (N) allele sequences which have the following allelic profiles: ST-NEW1 \[N-8-8-N-6-27-6\]; ST-NEW2 \[25-8-N-17-10-N-6\] (see also <http://efaecium.mlst.net/> and <http://efaecalis.mlst.net/>). ERY(i), erythromycin (intermediate); TET, tetracycline; MLST, Multi-locus sequence typing; ST, sequence type (of MLST); n.d., not determined.

Conclusions {#S4}
===========

A microbiological and molecular analysis of the enterococcal isolates from stool colonizations in newborn infants of a neonatal ICU revealed prevalence of colonizing strain types. Hospital-associated strain types or multi-resistant variants were not identified. Nevertheless, also colonizing strain types could cause endogenous enterococcal infections; however, the pathogens causing the described invasive infections could not been identified here. Cross transmission of enterococcal isolates among newborns attending the neonatal ICU at the same time was shown. To elucidate the source of these early colonizing isolates, an independent and comprehensive follow-up study including stool sampling and subsequent analyses from babies\' mothers and medical staff is planned.
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